

Title (en)

COMBINATION PREPARATION WITH AN ER-BETA SELECTIVE ESTROGEN AND A SERM

Title (de)

KOMBINATIONSPRÄPARATE AUS EINEM ER-BETA-SELEKTIVEN ESTROGEN UND EINEM SERM

Title (fr)

PREPARATIONS COMBINEES CONSTITUEES D'UN OESTROGENE SELECTIF DE L'ER-BETA ET D'UN SERM

Publication

**EP 1307229 A1 20030507 (DE)**

Application

**EP 01974107 A 20010803**

Priority

- DE 10039199 A 20000810
- EP 0109008 W 20010803

Abstract (en)

[origin: WO0211765A1] A novel medicament for the treatment of estrogen-deficient disease states is disclosed. Said medicament is a combination preparation comprising an ER<sub>ss</sub>-selective estrogen and an ER alpha -selective antiestrogen or SERM (Selective Estrogen Receptor Modulator). The antiestrogen or SERM which is a component of the combination preparation is preferably selective for the periphery. The preparation is suitable for an organ-specific estrogen therapy and has clear advantages over conventional therapies. Due to the combination of ER alpha -selective SERM and ER<sub>ss</sub>-estrogen the preparation permits a complete protection against bone loss caused by estrogen deficiency. The components of the medicament also have a synergistic effect with respect to the inhibition of inflammation inducing genes, in particular in inflammatory disorders such as atherosclerosis and arthritis, or neurodegenerative diseases such as Alzheimers and multiple sclerosis. Furthermore, positive effects on cognition and mood may be expected. The protective estrogen-like effects are achieved, with no expectation of proliferation effects on breasts or uterus.

IPC 1-7

**A61K 45/06**

IPC 8 full level

**A61K 45/00** (2006.01); **A61K 45/06** (2006.01); **A61K 31/00** (2006.01); **A61K 31/56** (2006.01); **A61K 31/565** (2006.01); **A61P 5/00** (2006.01); **A61P 5/24** (2006.01); **A61P 5/30** (2006.01); **A61P 5/32** (2006.01); **A61P 9/00** (2006.01); **A61P 9/10** (2006.01); **A61P 13/08** (2006.01); **A61P 15/12** (2006.01); **A61P 19/00** (2006.01); **A61P 19/02** (2006.01); **A61P 19/10** (2006.01); **A61P 25/20** (2006.01); **A61P 25/28** (2006.01); **A61P 29/00** (2006.01); **A61P 37/00** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP US)

**A61K 31/00** (2013.01 - EP US); **A61K 31/565** (2013.01 - EP US); **A61K 45/06** (2013.01 - EP US); **A61P 5/00** (2017.12 - EP); **A61P 5/24** (2017.12 - EP); **A61P 5/30** (2017.12 - EP); **A61P 5/32** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 13/08** (2017.12 - EP); **A61P 15/12** (2017.12 - EP); **A61P 19/00** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 19/10** (2017.12 - EP); **A61P 25/20** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP)

Citation (search report)

See references of WO 0211765A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated extension state (EPC)

LT LV RO SI

DOCDB simple family (publication)

**WO 0211765 A1 20020214**; AU 9372001 A 20020218; DE 10039199 A1 20020221; EP 1307229 A1 20030507; JP 2004505929 A 20040226; US 2004053898 A1 20040318

DOCDB simple family (application)

**EP 0109008 W 20010803**; AU 9372001 A 20010803; DE 10039199 A 20000810; EP 01974107 A 20010803; JP 2002517099 A 20010803; US 34416103 A 20030926